No Data
No Data
hunan fangsheng pharmaceutical (603998.SH) announced a semi-annual dividend of 0.05 yuan per share, with the record date set as October 18th.
hunan fangsheng pharmaceutical (603998.SH) announced that the company will implement the 2024 interim equity distribution, with a distribution per share...
Hunan Fangsheng Pharmaceutical (603998.SH): the chinese patent medicine produced is mainly sold in hospitals.
On September 25, Ge Longhui reported that hunan fangsheng pharmaceutical (603998.SH) stated on the interactive platform that currently, the Chinese patent medicines produced by the company are mainly sold in hospitals.
Hunan Fangsheng Pharmaceutical (603998.SH): Received the pharmaceutical registration acceptance notification for the Blood-nourishing Wind-dispelling Pain-relieving Granules.
Gelonghui, September 18th, Hunan Fangsheng Pharmaceutical (603998.SH) announced that in August 2024, its wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Jianmeng Pharmaceutical") completed the toxicology test of the YXQFZT granules (formerly known as Nuo Li Tong granules) and submitted the application for marketing authorization to the National Medical Products Administration. On September 13, 2024, Jianmeng Pharmaceutical received the "Acceptance Notice" for the YXQFZT granules. The YXQFZT granules are based on the representative prescription of the modern famous Chinese medicine expert Mr. Zhang Xichun, known as the "Sheng Xian Tang" formula, and can directly raise and nourish the qi and blood to the head.
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
Hunan Fangsheng Pharmaceutical's (SHSE:603998) Weak Earnings May Only Reveal A Part Of The Whole Picture
No Data
No Data